Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

Trial Profile

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Afatinib (Primary) ; Alectinib (Primary) ; Alpelisib (Primary) ; Atezolizumab (Primary) ; Axitinib (Primary) ; Bevacizumab (Primary) ; Cabozantinib (Primary) ; Cobimetinib (Primary) ; Crizotinib (Primary) ; Dabrafenib (Primary) ; Dacomitinib (Primary) ; Durvalumab (Primary) ; Entrectinib (Primary) ; Erdafitinib (Primary) ; Erlotinib (Primary) ; Ipilimumab (Primary) ; Lenvatinib (Primary) ; Lorlatinib (Primary) ; Nilotinib (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Palbociclib (Primary) ; Panitumumab (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Regorafenib (Primary) ; Ribociclib (Primary) ; Rucaparib (Primary) ; Sunitinib (Primary) ; Talazoparib (Primary) ; Trametinib (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
  • Indications Adrenal cancer; Advanced breast cancer; B-cell lymphoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Glioblastoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Salivary gland cancer; Sarcoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DRUP
  • Most Recent Events

    • 24 Oct 2023 Results (n=30) assessing safety and efficacy of crizotinib in METmut aNSCLC patients, presented at the 48th European Society for Medical Oncology Congress.
    • 24 Oct 2023 Results (n=1019) assessing the impact of these protocol waivers on patient safety and treatment efficacy, presented at the 48th European Society for Medical Oncology Congress.
    • 31 Aug 2023 Results from DRUP and Australian MoST , for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib published in the International Journal of Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top